Vitamin D levels not associated with adverse outcomes in European MS patients

WEST PALM BEACH, Florida — Genetically predicted levels of 25-hydroxyvitamin D were generally not associated with adverse disease outcomes in MS patients of European ancestry, according to a study presented at ACTRIMS Forum.
“There’s been an ongoing debate in the scientific world about the effects of vitamin D on disease prognosis,” Eleni Vasileiou, postdoctoral researcher in neuroimmunology at Johns Hopkins Hospital, said in the presentation. “There have been studies that reported a protective effect of vitamin D supplementation, but this could not be validated

WEST PALM BEACH, Florida — Genetically predicted levels of 25-hydroxyvitamin D were generally not associated with adverse disease outcomes in MS patients of European ancestry, according to a study presented at ACTRIMS Forum.
“There’s been an ongoing debate in the scientific world about the effects of vitamin D on disease prognosis,” Eleni Vasileiou, postdoctoral researcher in neuroimmunology at Johns Hopkins Hospital, said in the presentation. “There have been studies that reported a protective effect of vitamin D supplementation, but this could not be validated